SBSB
AGN

Sullivan, Bruyette, Speros & Blaney’s Allergan plc AGN Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-925
Closed -$214K – 146
2016
Q2 		$214K Buy
+925
New +$213K 0.02% 125

Other funds holding AGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's AGN Position: Q3 2016 in Review

Sullivan, Bruyette, Speros & Blaney sold out of Allergan plc (AGN) in Q3 2016, closing a stake of 925 shares — an estimated $214K sold.

Sullivan, Bruyette, Speros & Blaney first reported a position in AGN in Q2 2016 and held it in 1 quarter. The position peaked at $214K in Q2 2016. 1,105 funds tracked by Wall St. Rank hold AGN as of Q3 2016.

  • Sullivan, Bruyette, Speros & Blaney reported no remaining Allergan plc position as of Q3 2016 after selling out during the quarter.
  • Sullivan, Bruyette, Speros & Blaney sold 925 Allergan plc shares in Q3 2016, an estimated $214K.
  • Sullivan, Bruyette, Speros & Blaney first reported a position in Allergan plc in Q2 2016 and held it in 1 quarter.
  • Sullivan, Bruyette, Speros & Blaney's Allergan plc position peaked at $214K in Q2 2016.
  • 1,105 funds tracked by Wall St. Rank held Allergan plc as of Q3 2016.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q3 2016, filed 14 Nov 2016.